论文部分内容阅读
[目的]评价DNA损伤修复相关基因在宫颈癌组织中的表达及其临床意义。[方法]纳入2008~2009年在复旦大学附属肿瘤医院行根治性手术并辅助同步放化疗的113例宫颈鳞状细胞癌患者,采用免疫组化法检测DNA损伤修复相关基因(Polζ,ERCC1,ERCC2和RAD52)在石蜡包埋组织中的蛋白表达水平。[结果 ]Polζ,ERCC1,ERCC2和RAD52的阳性表达率分别为22.1%,46.0%,48.7%和20.4%。Kaplan-Meier生存分析表明Polζ蛋白表达阳性的患者无进展生存期更短(32个月vs 34个月,P=0.008)。多因素生存分析显示Polζ是肿瘤复发的重要因素(adjusted HR=7.79,95%CI:2.21~27.52,P=0.001)。[结论]Polζ可作为宫颈癌判断预后的预测因素,这可能是由于宫颈癌患者潜在的放化疗抵抗导致的,该机制值得进一步研究。
[Objective] To evaluate the expression of DNA damage repair related genes in cervical cancer and its clinical significance. [Methods] The 113 squamous cell carcinoma patients with cervical squamous cell carcinoma who underwent radical surgery and concurrent chemoradiotherapy from 2008 to 2009 in Cancer Hospital of Fudan University were enrolled in this study. Immunohistochemistry was used to detect the expression of DNA damage repair related genes (Polζ, ERCC1, ERCC2 And RAD52) in paraffin-embedded tissues. [Results] The positive rates of Polζ, ERCC1, ERCC2 and RAD52 were 22.1%, 46.0%, 48.7% and 20.4% respectively. Kaplan-Meier survival analysis showed that progression-free survival was shorter in patients with positive Polζ protein expression (32 months vs 34 months, P = 0.008). Multivariate survival analysis showed that Polζ was an important factor in tumor recurrence (adjusted HR = 7.79, 95% CI: 2.21-27.52, P = 0.001). [Conclusion] Polζ can be used as a predictor of cervical cancer prognosis, which may be due to the potential radiotherapy and chemotherapy resistance in patients with cervical cancer, the mechanism deserves further study.